Completed PHASE2 INTERVENTIONAL NCT00185146

Efficacy and Safety of Pactimibe in Patients With Atherosclerosis

Effect of Pactimibe on the Progression of Atherosclerosis as Measured by 2-D and 3-D Carotid Ultrasound

Sponsor: Sankyo Pharma Gmbh

Interventions Pactimibe

Updated 7 times since 2017 Last updated: Mar 27, 2007 Started: Sep 30, 2002 Completion: Aug 31, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Atherosclerosis, this trial is completed. The trial is conducted by Sankyo Pharma Gmbh and has accumulated 7 data snapshots since 2002. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Mar 2024 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Mar 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Sep 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Sep 2017 [monthly]

Completed PHASE2

First recorded

Sep 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sankyo Pharma Gmbh

Data source: Daiichi Sankyo

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Munich, Germany